# Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

> **NCT04377503** · PHASE2 · TERMINATED · sponsor: **Hospital Sao Domingos** · enrollment: 30 (actual)

## Conditions studied

- Cytokine Release Syndrome
- Covid-19

## Interventions

- **DRUG:** Tocilizumab 180 MG/ML
- **DRUG:** Methylprednisolone Sodium Succinate

## Key facts

- **NCT ID:** NCT04377503
- **Lead sponsor:** Hospital Sao Domingos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-01
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-11-30
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The number of critically ill patients wirh COVID-19 decrease abruptly
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377503, "Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04377503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*